Statistics

Total Visits

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER214

Select a period of time:

Number of views in the range

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER210

Views

Views
April 20240
May 20240
June 20241
July 20241
August 20242
September 20246
October 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States4
 

Top cities views

Views
Chicago1
Fort Worth1
Prineville1